Miller Andrew Craig
Transaction: 05/27/2026
OTHER
Change
0
Price
Not reported
Filing
05/29/2026
Type
OTHER
Alto Neuroscience, Inc.
ANRO • Biotechnology
$24.41
— 0.00 (0.00%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$1.05B
Growth
-100.0%
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.03Healthy liquidity · 15.69Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:10 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$24.41
Change0.00%
Shares Out42.81M
Market Cap$1.05B
Enterprise Value$808.38M
52W Range3.05 - 33.67
Beta1.09
P/E-12.41
P/B4.77
P/FCF-15.18
EV/EBITDA-9.75
EV/FCF-11.74
Price$24.41
Change0.00%
Shares Out42.81M
Market Cap$1.05B
Enterprise Value$808.38M
52W Range3.05 - 33.67
Beta1.09
P/E-12.41
P/B4.77
P/FCF-15.18
EV/EBITDA-9.75
EV/FCF-11.74
Earnings Yield-8.06%
FCF Yield-6.59%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.03
Current Ratio15.69
Quick Ratio15.69
Revenue 5Y-100.00%
Target$39.25
Target Upside60.79%
Target Median$36.50
Target Range24.00 - 60.00
Volume924.94K
Avg Volume453.12K
EPS Surprise-0.24
Investment DNA
How strong this company looks for long-term investors
44
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
75/100
Why this score▼
Manageable debt level · 0.03Healthy liquidity · 15.69Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 9 analyst votes · 2026-10-20
94/100
Bullish
Bullish
8
Hold
1
Bearish
0
Price Target
2026-08-14
Low
$24.00
Mean
$36.40
Median
$36.00
High
$50.00
Insider Transactions
Recent executive and insider activity
⚠ 1 high-volume insider sell detected
Miller Andrew Craig
Transaction: 05/27/2026
BUY
Change
+26,000
Price
$20.44
Filing
05/29/2026
Type
BUY
Etkin Amit
Transaction: 05/14/2026
SELL
Change
-400,000
Price
Not reported
Filing
05/15/2026
Type
SELL
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Miller Andrew Craig | OTHER | 0 | Not reported | 05/27/2026 | 05/29/2026 |
| Miller Andrew Craig | BUY | +26,000 | $20.44 | 05/27/2026 | 05/29/2026 |
| Etkin Amit | SELL | -400,000 | Not reported | 05/14/2026 | 05/15/2026 |
| York Gwill | BUY | +10,958 | $24.63 | 05/12/2026 | 05/14/2026 |
| Dreyfus Andrew | BUY | +10,958 | $24.63 | 05/12/2026 | 05/14/2026 |
| Manji Husseini | BUY | +10,958 | $24.63 | 05/12/2026 | 05/14/2026 |
| Cox Christopher Nixon | BUY | +10,958 | $24.63 | 05/12/2026 | 05/14/2026 |
| Sanchez Ramiro | BUY | +10,958 | $24.63 | 05/12/2026 | 05/14/2026 |
| Smith Nicholas Conrad | SELL | -2,806 | $19.69 | 03/01/2026 | 03/03/2026 |
| Etkin Amit | SELL | -6,227 | $19.69 | 03/01/2026 | 03/03/2026 |
| Hanley Jr. Michael Conick | BUY | +131,000 | $16.71 | 02/11/2026 | 02/13/2026 |
| Smith Nicholas Conrad | BUY | +200,000 | $16.71 | 02/11/2026 | 02/13/2026 |
| Savitz Adam | BUY | +124,000 | $16.71 | 02/11/2026 | 02/13/2026 |
| Etkin Amit | BUY | +306,000 | $16.71 | 02/11/2026 | 02/13/2026 |
| Sanchez Ramiro | BUY | +3,806 | $16.59 | 01/02/2026 | 01/06/2026 |
| Manji Husseini | BUY | +4,228 | $16.59 | 01/02/2026 | 01/06/2026 |
| Cox Christopher Nixon | BUY | +7,189 | $16.59 | 01/02/2026 | 01/06/2026 |
| York Gwill | BUY | +5,243 | $16.59 | 01/02/2026 | 01/06/2026 |
| Sanchez Ramiro | OTHER | 0 | Not reported | 08/12/2025 | 08/14/2025 |
| Sanchez Ramiro | BUY | +3,928 | $3.18 | 08/12/2025 | 08/14/2025 |